The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid to focus resources on a pair of cancer cell therapies.

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

The hold, placed by the FDA on an early-stage clinical trial of an experimental BET inhibitor, stems from a recent ...

Cancer completely disappeared from two-thirds of 24 patients treated with a combination of the antibody petosemtamab and ...

Vyne Therapeutics’ attempt to develop a safer, more tolerable BET inhibitor has hit turbulence. | Vyne Therapeutics’ attempt ...

What if business leaders approached strategy the way scientists design gene delivery vectors? In biotechnology, precision, ...

Scientists have launched a miniature lab into Earth's orbit, which contains microbes designed to produce proteins in space.

The transaction, which sources say could be agreed upon as soon as Monday, would price SpringWorks at $47 per share, totaling ...

The CEO and board chair of Belgian biotech Galapagos has announced plans to leave the islands. Paul Stoffels, M.D., will ...

The patent application covers the use of 3-Methylmethcathinone (3-MMC) in combination with Palmitoylethanolamide (PEA). This innovative combination aims to address the complex neurobiological and ...

Genomics company, Integrated DNA Technologies, is rewriting the future of genomics, pioneering new innovations in a bold move ...

Northwestern University spinout Grove Biopharma, a synthetic biology specialist developing a platform known as Bionic ...